Itacitinib in Treating Patients With Refractory Metastatic/Advanced Sarcomas

Inclusion Criteria

• •Subjects \>= 18 years old
• •Must have a histologically confirmed diagnosis of sarcoma with one of the following subtypes:
• •* Cohort 1: Leiomyosarcoma
• •* Cohort 2: Undifferentiated pleiomorphic sarcoma
• •* Cohort 3: Synovial sarcoma or myxoid/round cell liposarcoma
• •* Cohort 4: Chondrosarcoma (all subtypes of chondrosarcoma are allowed)
• •Subjects enrolling to cohorts 1, 2, or 3 must have received at least two prior lines of systemic therapy. Subjects enrolling to cohort 4 only may have received any number of prior lines of systemic therapy or may be treatment naïve
• •All ongoing toxicities related to prior therapies must be resolved to grade 1 or better (except alopecia)
• •Subjects must have one or more measurable lesions, as determined by Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1 assessed by computed tomography (CT) or magnetic resonance imaging (MRI)
• •Subjects must have at least one superficial lesion accessible for multiple biopsies; the tumor being biopsied cannot have been previously targeted for radiation therapy or have previously received intra-lesional treatment
• •\* NOTE: Superficial lesions previously targeted with radiation therapy that have demonstrated significant new growth via radiological imaging may be targeted for biopsy, with sponsor-investigator approval.
• •Total bilirubin level =\< 1.5 x the upper limit of normal (ULN) range mg/dL
• •Aspartate aminotransferase (AST) =\< 2.5 x ULN and alanine aminotransferase (ALT) levels =\< 2.5 x ULN
• •Alkaline phosphatase \< 2.5 x ULN
• •Serum creatinine =\< 1.5 x ULN
• •Calculated creatinine clearance \>= 30 mL/min using the Cockcroft-Gault formula may be included
• •Absolute neutrophil count (ANC) \>= 1.5 × 10\^9/L
• •Platelet count \>= 100 x 10\^9/L; transfusion is permitted as clinically indicated
• •Hemoglobin \>= 9 g/dL
• •\* Transfusion is permitted as clinically indicated
• •Subjects must have a life expectancy \>= 6 months, as determined by the treating physician
• •Eastern Cooperative Oncology Group (ECOG) performance status =\< 2 or Karnofksy performance status \>= 60
• •Male or non-pregnant and non-breast feeding female:
• •* Females of child-bearing potential must agree to use highly effective contraception without interruption from initiation of therapy and while on study medication and have a negative serum pregnancy test (beta - human chorionic gonadotropin \[hCG\]) result at screening and agree to ongoing pregnancy testing during the course of the study, and at the end of study treatment; a highly effective method of contraception is defined as one that results in a low failure rate (that is, \< 1% per year), when used consistently and correctly, such as implants, injectables, combined oral contraceptives, some intrauterine contraceptive devices, sexual abstinence, or a vasectomized partner
• •* Male subjects must practice abstinence or agree to use a condom during sexual contact with a pregnant female or a female of childbearing potential while participating in the study
• •Ability to understand and sign informed consent document
• •Willingness and ability to comply with scheduled visits, laboratory tests, and other study procedures